Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922221 | 1.00 | MAPT (0.31) | MAPTPOLBGAAG6PDL3MBTL1 | |
| SCHEMBL20898714 | 1.00 | MAPT (0.31) | MAPTPOLBGAAG6PDL3MBTL1 | |
| SCHEMBL18586582 | 0.86 | MAPT (0.31) | MAPTPOLB | |
| SCHEMBL8400768 | 0.81 | — | — | |
| SCHEMBL16212100 | 0.77 | NOTUM (0.31) | — | |
| SCHEMBL16464218 | 0.75 | — | — | |
| SCHEMBL22634130 | 0.74 | LMNA (0.35) | MAPTL3MBTL1 | |
| SCHEMBL21081462 | 0.74 | LMNA (0.35) | MAPTL3MBTL1 | |
| SCHEMBL504706 | 0.74 | LMNA (0.35) | MAPTL3MBTL1 | |
| SCHEMBL12897446 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117980290-A | Cyanopyridine and cyanopyrimidine BCL6 degrading agents | 达纳－法伯癌症研究所公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | MAPT 3752/4885POLB 3413/4885GAA 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.